Dubov A, Krakower DS, Rockwood N, Montgomery S, Shoptaw S. Provider implicit bias in prescribing HIV pre-exposure prophylaxis (PrEP) to people who inject drugs. J Gen Intern Med. 2023 Oct;38(13):2928-35. doi: 10.1007/s11606-023-08040-7
Mansfield C, Botha W, Vondeling GT, Klein K, Wang K, Singh J, Hackshaw MD. Patient preferences for features of HER2-targeted treatment of advanced or metastatic breast cancer: a discrete-choice experiment study. Breast Cancer. 2023 Jan;30(1):23-35. doi: 10.1007/s12282-022-01394-6
John NM, Wright SJ, Gavan SP, Vass CM. The role of information provision in economic evaluations of non-invasive prenatal testing: a systematic review. Eur J Health Econ. 2019 Nov;20(8):1123-31. doi: 10.1007/s10198-019-01082-x
Pead E, Megaw R, Cameron J, Fleming A, Dhillon B, Trucco E, MacGillivray T. Automated detection of age-related macular degeneration in color fundus photography: a systematic review. Surv Ophthalmol. 2019 Jul 1;64(4):498-511. doi: 10.1016/j.survophthal.2019.02.003
Wilson MR, Bergman A, Chevrou-Severac H, Selby R, Smyth M, Kerrigan MC. Cost-effectiveness of vedolizumab compared with infliximab, adalimumab, and golimumab in patients with ulcerative colitis in the United Kingdom. Eur J Health Econ. 2017 Mar;19(2):229-40. doi: 10.1007/s10198-017-0879-5.
Mandl KD, Olson KL, Mines D, Liu C, Tian F. Provider collaboration: cohesion, constellations, and shared patients. J Gen Intern Med. 2014 Nov;29(11):1499-505. doi: 10.1007/s11606-014-2964-0
Rothman KJ. Six persistent research misconceptions. J Gen Intern Med. 2014 Jul;29(7):1060-4. doi: 10.1007/s11606-013-2755-z
Pignone M, Earnshaw S, McDade C, Pletcher MJ. Effect of including cancer mortality on the cost-effectiveness of aspirin for primary prevention in men. J Gen Intern Med. 2013 Oct;28(11):1483-91.
Beard SM, von Scheele BG, Nuki G, Pearson IV. Cost-effectiveness of febuxostat in chronic gout. Eur J Health Econ. 2013 May;Advance online publication.
Candrilli SD, Kuznik A. The prevalence and overlap of select cardiovascular comorbidities among dyslipidemic US adults aged 65 years or older, stratified by lipid-lowering medication use. Poster presented at the 31st Annual Meeting of the Society of General Internal Medicine; April 2008. Pittsburg, PA. [abstract] J Gen Intern Med. 2008 Apr; 23(Supplement 2):419.
Greiner W, Lehmann K, Earnshaw S, Bug C, Sabatowski R. Economic evaluation of Durogesic in moderate to severe, nonmalignant, chronic pain in Germany. Eur J Health Econ. 2006 Dec 1;7(4):290-6.
Pignone M, Earnshaw S, Tice JA, Pletcher M, Wilson M. Aspirin, statins, or both therapies for primary prevention of myccardial infarction: a cost-utility analysis. J Gen Intern Med. 2004 Jan 1;19:121.
Lehmann K, Radbruch L, Gockel HH, Neighbors D, Nuyts G. Costs of opioid therapy for chronic nonmalignant pain in Germany: an economic model comparing transdermal fentanyl (Duragesic) with controlled release morphine. Eur J Health Econ. 2002;3:111-9. doi: 10.1007/s10198-002-0097-6.
Mines D, Fosnocht KM, Berlin JA, Strom BL. Can primary care physicians diagnose innocent heart murmurs? Presented at the 1999 22nd Annual Meeting of the Society for General Internal Medicine; May 1, 1999. San Francisco, CA. [abstract] J Gen Intern Med. 1999 Feb; 14(Suppl 2):113. doi: 10.1046/j.1525-1497.1999.1420005.x